Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6421300 | 0.88 | CHRM3 (0.48) | CHRM3HDAC3HDAC1HDAC2BCHE | |
| SCHEMBL830217 | 0.86 | USP30 (0.45) | KDM4EPKMTGFBR1USP30CHRM3 | |
| SCHEMBL6205109 | 0.81 | KDM4E (0.52) | KDM4EPKMTGFBR1CHRM3GPR119 | |
| SCHEMBL17205165 | 0.80 | TGFBR1 (0.57) | KDM4EPKMTGFBR1CHRM3ACHE | |
| SCHEMBL14560 | 0.78 | LIPE (0.48) | — | |
| SCHEMBL13261270 | 0.76 | STS (0.47) | KDM4EPKMUSP30GPR119 | |
| SCHEMBL17796971 | 0.75 | CHRM3 (0.53) | CHRM3 | |
| SCHEMBL17796970 | 0.75 | CHRM3 (0.53) | CHRM3 | |
| SCHEMBL12105458 | 0.75 | MEN1 (0.42) | USP30HDAC1 | |
| SCHEMBL1294831 | 0.75 | KMT2A (0.59) | KDM4EUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2005-12-15 | — | — | US | disclosed |
| EP-1549278-A4 | M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2005-12-14 | — | — | EP | disclosed |
| EP-1549278-A2 | M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004012684-A2 | M3MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | CHRM3, CHRM2, CHRM5 | KDM4E 4337/4885PKM 4019/4885TGFBR1 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.